Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Celecoxib in Crohn's Disease
NCT00177866Phase 4Terminated
- Sponsor
- University of Pittsburgh
- Start
- Dec 2003
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of celecoxib oral solution in Crohn's disease (2 arms), sponsored by University of Pittsburgh. Primary endpoint: Crohn's Disease Activity Index at 18 weeks. Started Dec 2003; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00177866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177866.